Dupilumab Reduces Exacerbations and Improves Lung Function in Children (6 to 11 Years) with Moderate-to-Severe Asthma and High Eosinophils (Poster 1)
Monday, May 1, 2023
1:00 PM – 2:30 PM ET
Location: Convention Center: 206
Publication Number: 3380.6
Daniel J. Jackson, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States; Eckard Hamelmann, University of Bielefeld, Bielefeld, Germany, Bielefeld, Nordrhein-Westfalen, Germany; Graham Roberts, University of Southampton, Southampton, England, United Kingdom; Leonard B. Bacharier, Vanderbilt University Medical Center, Nashville, TN, United States; Nicholas M. Jellots, Sanofi-Genzyme, Indiana, PA, United States; Arman Altincatal, Sanofi, Cambridge, MA, United States; Rebecca Gall, Regeneron Pharmaceuticals, Sleepy Hollow, NY, United States; Olivier Ledanois, SANOFI, Paris, Ile-de-France, France; Juby A. Jacob-Nara, Sanofi, Hillsborough, NJ, United States; Amr Radwan, Regeneron, Tarrytown, NY, United States; Paul J. Rowe MD, Sanofi, randolph, NJ, United States; yamo deniz, Regeneron, Tarrytown, NY, United States
Presenting Author(s)
Nicholas M. Jellots, PharmD, BCPS (he/him/his)
Medical Science Liaison Sanofi Indiana, Pennsylvania, United States
Disclosure(s):
Daniel J. jackson, MD: AstraZeneca (Ongoing) (Products/Services: Advisory Committee); Avillion (Ongoing) (Products/Services: Advisory Committee); GlaxoSmithKline (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Pfizer (Terminated, October 1, 2022) (Products/Services: Consultant); Regeneron (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Sanofi (Ongoing) (Products/Services: Consultant)
Eckard Hamelmann, Prof. Dr., M.D., Ph.D.: Aimmune Therapeutics (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); ALK (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); AstraZeneca (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); Boehringer Ingelheim (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); GSK (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); HAL Allergy (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); Novartis (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); Nutricia (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); Sanofi (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); Stallergenes Greer (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness)
Graham Roberts, DM, MSc, MA, BM, BCh: ALK-Abelló (Ongoing) (Products/Services: Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness); Merck (Ongoing) (Products/Services: Board Member or Executive Role)
Leonard Bacharier, MD: AstraZeneca (Ongoing) (Products/Services: Board Member or Executive Role, Consultant, Speaker Honorarium including speakers bureau, symposia, and expert witness); Cystic Fibrosis Foundation (Ongoing) (Products/Services: Board Member or Executive Role); DBV Technologies (Ongoing) (Products/Services: Board Member or Executive Role); GSK (Ongoing) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness); NIH (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); OMPharma (Ongoing) (Products/Services: Consultant); Regeneron Pharmaceuticals, Inc. (Ongoing) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness); Sanofi (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Speaker Honorarium including speakers bureau, symposia, and expert witness)
Nicholas M. Jellots, PharmD, BCPS: Sanofi (Ongoing) (Products/Services: Employment with an ineligible company, Employment with an ineligible company)
Arman Altincatal, MS: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Rebecca Gall, MD: Regeneron Pharmaceuticals (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)
Olivier Ledanois, Medical degree: SANOFI (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)
Juby A. Jacob-Nara, MD DHSc MPH MBA: Sanofi (Ongoing) (Products/Services: Employment with an ineligible company)
Amr Radwan, MA MBBChir cantab: Regeneron (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)
Paul J. Rowe, MD ATSF: Sanofi (Ongoing) (Products/Services: Employment with an ineligible company)
Yamo Deniz, MD: Regeneron (Ongoing) (Products/Services: Employment with an ineligible company)
